Substitutions at position 105 in SHV family β-lactamases decrease catalytic efficiency and cause inhibitor resistance

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5678-5686

  Li, Mei ^a   Conklin, Benjamin C ^a   Taracila, Magdalena A ^a   Hutton, Rebecca A ^a   Skalweit, Marion J ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMPICILLIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; BICYCLIC 6 METHYLIDENE PENEM; CARBAPENEMASE; CEFALOTIN; CEFOPERAZONE; CEFTAZIDIME; CEFTRIAXONE; CLAVULANIC ACID; NITROCEFIN; PENEM DERIVATIVE; PIPERACILLIN; SERINE; TAZOBACTAM; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CATALYSIS; CONTROLLED STUDY; DNA SEQUENCE; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME KINETICS; ESCHERICHIA COLI; HYDROLYSIS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MODEL; MUTAGENESIS; PRIORITY JOURNAL; PROTON TRANSPORT; RAMAN SPECTROMETRY;

AMINO ACID SUBSTITUTION; AMPICILLIN; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BIOCATALYSIS; CEPHALOSPORINS; CLAVULANIC ACID; ENZYME INHIBITORS; ESCHERICHIA COLI; KINETICS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DOCKING SIMULATION; MUTAGENESIS, SITE-DIRECTED; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; SULBACTAM; THIENAMYCINS;

EID: 84868016790     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00711-12     Document Type: Article

References (46)

1. Bethel CR, et al. 2006. Role of Asp104 in the SHV β-lactamase. Antimicrob. Agents Chemother. 50:4124-4131.
2. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
3. Bush K. 2010. Alarming β-lactamase-mediated resistance in multidrugresistant Enterobacteriaceae. Curr. Opin. Microbiol. 13:558-564.
4. Bush K, Jacoby GA. 2010. Updated functional classification of β-lactamases. Antimicrob. Agents Chemother. 54:969-976.
5. CLSI. 2011. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. M100-S21. CLSI, Wayne, PA.
6. Di Gleria K, Halliwell CM, Jacob C, Hill HA. 1997. Site-specific introduction of an electroactive label into a non-electroactive enzyme (β-lactamase I). FEBS Lett. 400:155-157.
7. Dixon M. 1965. Graphical determination of equilibrium constants. Biochem. J. 94:760-762.
8. Doucet N, De Wals PY, Pelletier JN. 2004. Site-saturation mutagenesis of Tyr-105 reveals its importance in substrate stabilization and discrimination in TEM-1 β-lactamase. J. Biol. Chem. 279:46295-46303.
9. Doucet N, Pelletier JN. 2007. Simulated annealing exploration of an active-site tyrosine in TEM-1 β-lactamase suggests the existence of alternate conformations. Proteins 69:340-348.
10. Doucet N, Savard PY, Pelletier JN, Gagné SM. 2007. NMR investigation of Tyr105 mutants in TEM-1 β-lactamase: dynamics are correlated with function. J. Biol. Chem. 282:21448-21459.
11. Drawz SM, et al. 2009. The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV β-lactamase: a study of ambler position Asn276. Biochemistry 48:4557-4566.
12. Drawz SM, Bonomo RA. 2010. Three decades of β-lactamase inhibitors. Clin. Microbiol. Rev. 23:160-201.
13. Dubois V, et al. 2004. SHV-49, a novel inhibitor-resistant β-lactamase in a clinical isolate of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48:4466 - 4469.
14. Dubois V, et al. 2008. Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant β-lactamase from Klebsiella pneumoniae. Antimicrob. Agents Chemother. 52:3792-3794.
15. Escobar WA, Miller J, Fink AL. 1994. Effects of site-specific mutagenesis of tyrosine 105 in a class A β-lactamase. Biochem. J. 303:555-558.
16. Frase H, Toth M, Champion MM, Antunes NT, Vakulenko SB. 2011. Importance of position 170 in the inhibition of GES-type β-lactamases by clavulanic acid. Antimicrob. Agents Chemother. 55:1556-1562.
17. Helfand MS, et al. 2003. Understanding resistance to β-lactams and β-lactamase inhibitors in the SHV β-lactamase: lessons from the mutagenesis of SER-130. J. Biol. Chem. 278:52724-52729.
18. Helfand MS, Hujer AM, Sönnichsen FD, Bonomo RA. 2002. Unexpected advanced generation cephalosporinase activity of the M69F variant of SHV β-lactamase. J. Biol. Chem. 277:47719-47723.
19. Helfand MS, et al. 2003. Following the reactions of mechanism-based inhibitors with β-lactamase by Raman crystallography. Biochemistry 42: 13386-13392. (Erratum, 42:15398).
20. Hujer AM, Bethel CR, Bonomo RA. 2004. Antibody mapping of the linear epitopes of CMY-2 and SHV-1 β-lactamases. Antimicrob. Agents Chemother. 48:3980-3988.
21. Hujer AM, Hujer KM, Bonomo RA. 2001. Mutagenesis of amino acid residues in the SHV-1 β-lactamase: the premier role of Gly238Ser in penicillin and cephalosporin resistance. Biochim. Biophys. Acta 1547:37-50.
22. Hujer AM, Hujer KM, Helfand MS, Anderson VE, Bonomo RA. 2002. Amino acid substitutions at Ambler position Gly238 in the SHV-1 β-lactamase: exploring sequence requirements for resistance to penicillins and cephalosporins. Antimicrob. Agents Chemother. 46:3971-3977.
23. Hujer AM, Page MG, Helfand MS, Yeiser B, Bonomo RA. 2002. Development of a sensitive and specific enzyme-linked immunosorbent assay for detecting and quantifying CMY-2 and SHV β-lactamases. J. Clin. Microbiol. 40:1947-1957.
24. Kitchel B, et al. 2010. Genetic factors associated with elevated carbap-enem resistance in KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 54:4201-4207.
25. Kuzin AP, et al. 2001. Inhibition of the SHV-1 β-lactamase by sulfones: crystallographic observation of two reaction intermediates with tazobactam. Biochemistry 40:1861-1866.
26. Kuzin AP, et al. 1999. Structure of the SHV-1 β-lactamase. Biochemistry 38:5720-5727.
27. Lavilla S, et al. 2008. Prevalence of qnr genes among extended-spectrum β-lactamase-producing enterobacterial isolates in Barcelona, Spain. J. Antimicrob. Chemother. 61:291-295.
28. Manageiro V, Ferreira E, Albuquerque L, Bonnet R, Caniça M. 2010. Biochemical study ofa new inhibitor-resistant β-lactamase, SHV-84, produced by a clinical Escherichia coli strain. Antimicrob. Agents Chemother. 54:2271-2272.
29. Mansour TS, et al. 2007. On the absolute configuration in 1,4-dihydrothiazepine covalent complexes derived from inhibition of class A and C β-lactamases with 6-methylidene penems. ChemMedChem 2:1713-1716.
30. Mendonça N, et al. 2008. The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. Antimicrob. Agents Chemother. 52:1806-1811.
31. Mendonça N, Nicolas-Chanoine MH, Caniça M. 2009. Diversity of the bla(SHV) genes. Diagn. Microbiol. Infect. Dis. 65:439-446.
32. Nukaga M, et al. 2003. Inhibition of class A and class C β-lactamases by penems: crystallographic structures ofa novel 1,4-thiazepine intermediate. Biochemistry 42:13152-13159.
33. Nukaga M, et al. 2008. Inhibition of class A β-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1. J. Am. Chem. Soc. 130:12656-12662.
34. Page MG. 2000. β-Lactamase inhibitors. Drug Resist. Updat. 3:109-125.
35. Papp-Wallace KM, Distler AM, Kasuboski C, Taracila M, Bonomo RA. 2010. Inhibitor resistance in the KPC-2 β-lactamase, a preeminent property of this class A β-lactamase. Antimicrob. Agents Chemother. 54:890-897.
36. Papp-Wallace KM, et al. 2010. Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 β-lactamase. Antimicrob. Agents Chemother. 54:2867-2877.
37. Papp-Wallace KM, et al. 2010. Elucidating the role of Trp105 in the KPC-2 β-lactamase. Protein Sci. 19:1714-1727.
38. Pattanaik P, et al. 2009. Strategic design of an effective β-lactamase inhibitor: LN-1-255, a 6-alkylidene-2'-substituted penicillin sulfone. J. Biol. Chem. 284:945-953.
39. Petersen PJ, et al. 2009. Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem β-lactamase inhibitor BLI-489. Antimicrob. Agents Chemother. 53:370-384.
40. Prinarakis EE, Miriagou V, Tzelepi E, Gazouli M, Tzouvelekis LS. 1997. Emergence of an inhibitor-resistant β-lactamase (SHV-10) derived from an SHV-5 variant. Antimicrob. Agents Chemother. 41:838-840.
41. Rholl DA, et al. 2011. Molecular Investigations of PenA-mediated β-lactam resistance in Burkholderia pseudomallei. Front. Microbiol. 2:139.
42. Swarén P, et al. 1999. X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 β-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid. Biochemistry 38:9570-9576.
43. Thomson JM, Distler AM, Prati F, Bonomo RA. 2006. Probing active site chemistry in SHV β-lactamase variants at Ambler position 244. Understanding unique properties of inhibitor resistance. J. Biol. Chem. 281: 26734-26744.
44. Venkatesan AM, et al. 2006. Structure-activity relationship of 6-methylidene penems bearing 6,5 bicyclic heterocycles as broad-spectrum β-lactamase inhibitors: evidence for 1,4-thiazepine intermediates with C7 R stereochemistry by computational methods. J. Med. Chem. 49:4623-4637.
45. Yigit H, et al. 2001. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45:1151-1161. (Erratum, 52:809, 2008).
46. Yigit H, et al. 2003. Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing β-lactamase KPC-2. Antimicrob. Agents Chemother. 47:3881-3889.